What is Design Therapeutics, Inc.'s G&A?

Design Therapeutics, Inc. (DSGN) reported G&A of $5.33M in Q1 2026.

How has Design Therapeutics, Inc.'s G&A changed year-over-year?

Design Therapeutics, Inc.'s G&A increased by 5.7% year-over-year, from $5.04M to $5.33M.

What is the long-term trend for Design Therapeutics, Inc.'s G&A?

Over 4 years (2021 to 2025), Design Therapeutics, Inc.'s G&A has grown at a 16.5% compound annual growth rate (CAGR), from $11.05M to $20.34M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Design Therapeutics, Inc. DSGN G&A

G&A at other companies

Intellia TherapeuticsNTLA

$34.84M+20.1%

CRISPR TherapeuticsCRSP

$17.18M-11.0%

Dyne Therapeutics, Inc.DYN

$24.39M+53.1%

Vor BiopharmaVOR

$17.57M+167%

Taysha Gene Therapies, Inc.TSHA

$9.68M+18.6%

Nektar TherapeuticsNKTR

$13.44M-44.8%

Other financials

Income statement

See full

Revenue-—

Operating income-$19.7M+3.5%

Net income-$17.6M+0.4%

EPS (diluted)-$0.29+6.5%

Balance sheet

See full

Cash & equivalents$12.8M-6.6%

Total debt$2.7M+27.7%

Total equity$218.1M-4.3%

Total assets$230.4M-3.0%

Cash flow

See full

Operating cash flow-$16.4M+2.1%

CapEx--100%

Free cash flow-$16.4M+2.6%

Valuation

See full

Market cap$860.66M+305%

Enterprise value$850.62M+324%

Profitability

See full

Operating margin-3,685.8%—

Net margin-3,663.7%—

Returns & leverage

See full

Return on equity-31.3%+19.5pp

Debt / equity0×0.0×

Current ratio22.3×-6.1×

Where this comes from

Reported directly by Design Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Design Therapeutics, Inc.’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Design Therapeutics, Inc.'s g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Design Therapeutics, Inc.'s G&A?: Design Therapeutics, Inc. (DSGN) reported G&A of $5.33M in Q1 2026.
How has Design Therapeutics, Inc.'s G&A changed year-over-year?: Design Therapeutics, Inc.'s G&A increased by 5.7% year-over-year, from $5.04M to $5.33M.
What is the long-term trend for Design Therapeutics, Inc.'s G&A?: Over 4 years (2021 to 2025), Design Therapeutics, Inc.'s G&A has grown at a 16.5% compound annual growth rate (CAGR), from $11.05M to $20.34M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.